News articles about Urogen Pharma (NASDAQ:URGN) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Urogen Pharma earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.2400335077489 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- -$0.73 Earnings Per Share Expected for Urogen Pharma Ltd (URGN) This Quarter (americanbankingnews.com)
- Zacks Investment Research Upgrades Urogen Pharma (URGN) to Buy (americanbankingnews.com)
- Analyzing Urogen Pharma (URGN) and Its Competitors (americanbankingnews.com)
- Urogen Pharma Ltd (URGN) Given Consensus Recommendation of “Buy” by Brokerages (americanbankingnews.com)
A number of brokerages recently weighed in on URGN. UBS raised shares of Urogen Pharma from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 4th. Oppenheimer reaffirmed a “buy” rating on shares of Urogen Pharma in a research note on Thursday, March 22nd. Jefferies Group reaffirmed a “buy” rating on shares of Urogen Pharma in a research note on Monday, March 19th. Ladenburg Thalmann reaffirmed a “buy” rating and issued a $65.00 price target on shares of Urogen Pharma in a research note on Friday, March 16th. Finally, Raymond James Financial raised shares of Urogen Pharma from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 4th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $45.50.
Urogen Pharma (NASDAQ:URGN) last released its earnings results on Thursday, March 15th. The company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.09). The business had revenue of $0.33 million for the quarter. equities analysts anticipate that Urogen Pharma will post -3.21 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Urogen Pharma (URGN) Earns Daily Media Sentiment Score of 0.23” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2018/04/17/urogen-pharma-urgn-earns-daily-media-sentiment-score-of-0-23.html.
Urogen Pharma Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.